- Home
- AGFY vs PRLD Comparison
AGFY vs PRLD Comparison
Compare AGFY & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGFY
- PRLD
- Stock Information
- Founded
- AGFY 2016
- PRLD 2016
- Country
- AGFY United States
- PRLD United States
- Employees
- AGFY N/A
- PRLD N/A
- Industry
- AGFY Military/Government/Technical
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- AGFY Consumer Discretionary
- PRLD Health Care
- Exchange
- AGFY Nasdaq
- PRLD Nasdaq
- Market Cap
- AGFY 50.6M
- PRLD 48.6M
- IPO Year
- AGFY 2021
- PRLD 2020
- Fundamental
- Price
- AGFY $22.76
- PRLD $0.80
- Analyst Decision
- AGFY
- PRLD Strong Buy
- Analyst Count
- AGFY 0
- PRLD 2
- Target Price
- AGFY N/A
- PRLD $4.50
- AVG Volume (30 Days)
- AGFY 19.5K
- PRLD 230.1K
- Earning Date
- AGFY 08-13-2025
- PRLD 08-11-2025
- Dividend Yield
- AGFY N/A
- PRLD N/A
- EPS Growth
- AGFY N/A
- PRLD N/A
- EPS
- AGFY N/A
- PRLD N/A
- Revenue
- AGFY $10,218,000.00
- PRLD $7,000,000.00
- Revenue This Year
- AGFY N/A
- PRLD N/A
- Revenue Next Year
- AGFY N/A
- PRLD N/A
- P/E Ratio
- AGFY N/A
- PRLD N/A
- Revenue Growth
- AGFY 9.42
- PRLD N/A
- 52 Week Low
- AGFY $2.71
- PRLD $0.61
- 52 Week High
- AGFY $84.44
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- AGFY 48.27
- PRLD 40.96
- Support Level
- AGFY $19.64
- PRLD $0.77
- Resistance Level
- AGFY $21.75
- PRLD $0.84
- Average True Range (ATR)
- AGFY 2.05
- PRLD 0.07
- MACD
- AGFY -0.36
- PRLD -0.02
- Stochastic Oscillator
- AGFY 33.88
- PRLD 9.35
About AGFY Agrify Corporation
Agrify Corp is a developer of branded inventive solutions for the cannabis and hemp industries. Its Senorita brand offers consumers hemp-derived tetrahydrocannabinol (THC) beverages that mirror cocktails like a margarita - in three flavors - classic Lime Jalapeno Margarita, Mango Margarita, and Paloma. In addition to beverages, Agrify has also historically been a provider of inventive cultivation and extraction solutions for the cannabis industry. Its comprehensive extraction product line, which includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.